Structure of the Collision Zone Between the Nazca Ridge and the Peruvian Convergent Margin: Geodynamic and Seismotectonic Implications

We study the structure and tectonics of the collision zone between the Nazca Ridge (NR) and the Peruvian margin constrained by seismic, gravimetric, bathymetric, and natural seismological data. The NR was formed in an on-ridge setting, and it is characterized by a smooth and broad shallow seafloor (swell) with an estimated buoyancy flux of ~7 Mg/s. The seismic results show that the NR hosts an oceanic lower crust 10–14 km thick with velocities of 7.2–7.5 km/s suggesting intrusion of magmatic material from the hot spot plume to the oceanic plate. Our results show evidence for subduction erosion in the frontal part of the margin likely enhanced by the collision of the NR. The ridge-trench collision zone correlates with the presence of a prominent normal scarp, a narrow continental slope, and (uplifted) shelf. In contrast, adjacent of the collision zone, the slope does not present a topographic scarp and the continental slope and shelf become wider and deeper. Geophysical and geodetic evidence indicate that the collision zone is characterized by low seismic coupling at the plate interface. This is consistent with vigorous subduction erosion enhanced by the subducting NR causing abrasion and increase of fluid pore pressure at the interplate contact. Furthermore, the NR has behaved as a barrier for rupture propagation of megathrust earthquakes (e.g., 1746 Mw 8.6 and 1942 Mw 8.1 events). In contrast, for moderate earthquakes (e.g., 1996 Mw 7.7 and 2011 Mw 6.9 events), the NR has behaved as a seismic asperity nucleating at depths >20 km

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Background: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. Methods: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0–1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0–2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4–6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. Findings: Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1·49 [95% CI 1·10–2·03]; p=0·011), with low heterogeneity across studies (I2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1·38 [95% CI 1·05–1·80]; p=0·019), and a higher odds of independent outcome (adjusted OR 1·50 [1·06–2·12]; p=0·022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4–6), compared with 102 (25%) patients in the control group (adjusted OR 0·76 [0·52–1·11]; p=0·15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2·06 [1·03–4·09]; p=0·040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5·58 [1·22–25·50]; p=0·024). Interpretation: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. Funding: None

Geochemistry, U-Pb SHRIMP zircon dating and Hf isotopes of the Gondwanan magmatism in NW Argentina: Petrogenesis and geodynamic implications

We have carried out zircon U-Pb SHRIMP dating and Hf isotope determinations as well as geochemical analyses on three plutonic units of Gondwanan magmatism that crop out in NW Argentina. Two episodes of different age and genesis have been identified. The older one includes gabbros and diorites (Río Grande Unit) of 267±3 Ma and granitoids (belonging to the Llullaillaco Unit) of 263±1 Ma (late Permian, Guadalupian); the parent magmas were generated in an intraplate environment and derived from an enriched mantle but were subsequently contaminated by crustal components. The younger rocks are granodiorites with arc signature (Chuculaqui Unit) and an age of 247±2 Ma (middle Triassic-Anisian). Hf isotope signature of the units indicates mantle sources as well as crustal components. Hf model ages obtained are consistent with the presence of crustal Mesoproterozoic (mainly Ectasian to Calymnian (TDM(c) =1.24 to 1.44 Ga-negative Hf(T)) and juvenile Cryogenian sources (TDM=0.65 to 0.79 Ga-positive eHf(T)), supporting the idea of a continuous, mostly Mesoproterozoic, basement under the Central Andes, as an extension of the Arequipa-Antofalla massif. The tectonic setting and age of the Gondwanan magmatism in NW Argentina allow to differentiate: a. Permian intra-plate magmatism developed under similar conditions to the upper section of the Choiyoi magmatism exposed in the Frontal Cordillera and San Rafael Block, Argentina; b. Triassic magmatism belonging to a poorly known subduction-related magmatic arc segment of mostly NS trend with evidence of porphyry type mineralization in Chile, allowing to extend this metallotect into Argentina

Structural evolution of a composite middle to lower crustal section: The Sierra de Pie de Palo, northwest Argentina.

The Sierra de Pie de Palo of northwest Argentina preserves middle to lower crustal metamorphic rocks that were penetratively deformed during Ordovician accretion of the Precordillera terrane to the Gondwana margin. New structural, petrologic, and geochronologic data from a 40 km structural transect reveals that the Sierra de Pie de Palo preserves a middle to lower crustal ductile thrust complex consisting of individual structural units and not an intact ophiolite and cover sequence. Top-to-the-west thrusting occurred intermittently on discrete ductile shear zones from ∼515 to ∼417 Ma and generally propagated toward the foreland with progressive deformation. Ordovician crustal shortening and peak metamorphic temperatures in the central portion of the Sierra de Pie de Palo were synchronous with retro-arc shortening and magmatic flare-up within the Famatina arc. Accretion of the Precordillera terrane resulted in the end of arc flare-up and the onset of synconvergent extension by ∼439 Ma. Continued synextensional to postextensional convergence was accommodated along progressively lower grade shear zones following terrane accretion and the establishment of a new plate margin west of the Precordillera terrane. The results support models of Cordilleran orogens that link voluminous arc magmatism to periods of regional shortening. The deformation, metamorphic, and magmatic history within the Sierra de Pie de Palo is consistent with models placing the region adjacent to the Famatina margin in the middle Cambrian and not as basement to the Precordillera terrane.Fil: Mulcahy, S. R.. University of Nevada; Estados Unidos. University of California at Davis; Estados UnidosFil: Roeske, S. M.. University of California at Davis; Estados UnidosFil: McClelland, W. C.. University of Iowa; Estados UnidosFil: Jourdan, F.. Curtin University; Australia. Berkeley Geochronology Center; Estados UnidosFil: Iriondo, A.. Universidad Nacional Autónoma de México; MéxicoFil: Renne, P. R.. Berkeley Geochronology Center; Estados Unidos. University of California at Berkeley; Estados UnidosFil: Vervoort, J. D.. Washington State University; Estados UnidosFil: Vujovich, Graciela Irene. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Geología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Background: Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurrent stroke compared with antiplatelet therapy. We hypothesised that anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, would reduce the risk of recurrent ischaemic stroke compared with aspirin among patients with PFO enrolled in the NAVIGATE ESUS trial. Methods: NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS. For this prespecified subgroup analysis, cohorts with and without PFO were defined on the basis of transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE). The primary efficacy outcome was time to recurrent ischaemic stroke between treatment groups. The primary safety outcome was major bleeding, according to the criteria of the International Society of Thrombosis and Haemostasis. The primary analyses were based on the intention-to-treat population. Additionally, we did a systematic review and random-effects meta-analysis of studies in which patients with cryptogenic stroke and PFO were randomly assigned to receive anticoagulant or antiplatelet therapy. Findings: Between Dec 23, 2014, and Sept 20, 2017, 7213 participants were enrolled and assigned to receive rivaroxaban (n=3609) or aspirin (n=3604). Patients were followed up for a mean of 11 months because of early trial termination. PFO was reported as present in 534 (7·4%) patients on the basis of either TTE or TOE. Patients with PFO assigned to receive aspirin had a recurrent ischaemic stroke rate of 4·8 events per 100 person-years compared with 2·6 events per 100 person-years in those treated with rivaroxaban. Among patients with known PFO, there was insufficient evidence to support a difference in risk of recurrent ischaemic stroke between rivaroxaban and aspirin (hazard ratio [HR] 0·54; 95% CI 0·22–1·36), and the risk was similar for those without known PFO (1·06; 0·84–1·33; pinteraction=0·18). The risks of major bleeding with rivaroxaban versus aspirin were similar in patients with PFO detected (HR 2·05; 95% CI 0·51–8·18) and in those without PFO detected (HR 2·82; 95% CI 1·69–4·70; pinteraction=0·68). The random-effects meta-analysis combined data from NAVIGATE ESUS with data from two previous trials (PICSS and CLOSE) and yielded a summary odds ratio of 0·48 (95% CI 0·24–0·96; p=0·04) for ischaemic stroke in favour of anticoagulation, without evidence of heterogeneity. Interpretation: Among patients with ESUS who have PFO, anticoagulation might reduce the risk of recurrent stroke by about half, although substantial imprecision remains. Dedicated trials of anticoagulation versus antiplatelet therapy or PFO closure, or both, are warranted. Funding: Bayer and Janssen